Diabetes

Smart Meter Introduces World’s First Cellular-Enabled Glucose Meter with Notifications and Multi-Language Capabilities

Retrieved on: 
Sunday, May 5, 2024
Mobile, Wireless, Technology, Medical Devices, Diabetes, Health Technology, Telemedicine, Virtual Medicine, Other Health, Biometrics, Biotechnology, Health, RPM, Pharmacy, Smart, Smart meter, Life, Smartphone, Blood, Patient, LED, Physician, American Telemedicine Association, Multimedia, Patient satisfaction, Howard University, Telehealth, Medical device

iGlucose Plus is available with Spanish language on-screen prompts providing improved access to care to a largely underserved patient population.

Key Points: 
  • iGlucose Plus is available with Spanish language on-screen prompts providing improved access to care to a largely underserved patient population.
  • (Photo: Business Wire)
    The iGlucose Plus is an innovative glucose meter that is easy to use and requires no synching, pairing, smartphone, or Wi-Fi.
  • The new iGlucose Plus is an excellent example of that,” said Casey Pittock, CEO of Smart Meter.
  • The new iGlucose Plus will be on display at the American Telemedicine Association show in Phoenix, Arizona May 5 – 7 at Smart Meter’s booth #1007.

Global and Regional Wound Debridement Market Analysis and Forecast, 2023-2024 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Health, Surgery, Medical Supplies, Medical Devices, Conditional sentence, Convatec, Smith & Nephew, Competitive landscape, Region, Diabetes, DeRoyal, Research, Obesity, Incidence, Patient, Ageing, Growth, Prevalence

The "Wound Debridement Market - A Global and Regional Analysis: Focus on Product, Region, Country-Level Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wound Debridement Market - A Global and Regional Analysis: Focus on Product, Region, Country-Level Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global wound debridement market is projected to experience substantial growth over the forecast period 2023-2030.
  • The market includes various types of products, such as ultrasonic debridement, mechanical debridement, enzymatic debridement, and surgical/sharp debridement.
  • The global wound debridement market (by region) has been dominated by North America, which held a 43.34% share in 2022.

Babson Diagnostics Partners with Cynergy Wellness, Inc.

Retrieved on: 
Saturday, May 4, 2024
Technology, Health Technology, Specialty, Other Science, Research, Medical Devices, Hospitals, Retail, Biotechnology, Women, Health, Seniors, Convenience Store, Practice Management, Men, General Health, Science, Nursing, Consumer, Medical Supplies, Diabetes, Hardware, Other Retail, Other Health, DTC, Safety, Blood, Partnership, Workplace, Babson, Diagnosis, Patient, Confidentiality, Pharmacy, Medical device

Babson Diagnostics, a science-first health care technology company, today announced a partnership with Cynergy Wellness, Inc., a privately-owned provider of nationwide physician services for workplace screening and consumer health.

Key Points: 
  • Babson Diagnostics, a science-first health care technology company, today announced a partnership with Cynergy Wellness, Inc., a privately-owned provider of nationwide physician services for workplace screening and consumer health.
  • Under the terms of the partnership, Cynergy will provide clinician oversight services for BetterWay™ blood testing orders placed directly by consumers.
  • “We are thrilled to partner with Cynergy Wellness as we launch BetterWay,” said David Stein, chief executive officer of Babson Diagnostics.
  • “We are proud to work with Babson Diagnostics in the launch of BetterWay direct-to-consumer blood testing.

Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, May 2, 2024
Diabetes, Health, Medical Devices, Sale, Tandem Diabetes Care, Economics, Depreciation, Webcast, Event, Adjustment, GAAP, Bank

Non-GAAP operating loss(1) totaled $40.5 million, or negative 21 percent of sales, compared to $44.4 million or negative 26 percent of sales.

Key Points: 
  • Non-GAAP operating loss(1) totaled $40.5 million, or negative 21 percent of sales, compared to $44.4 million or negative 26 percent of sales.
  • (1) A reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures and additional information can be found in Table E “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.
  • The Company’s non-GAAP guidance for the fiscal year ending December 31, 2024 is set forth below.
  • A reconciliation of each of the historical GAAP financial measures to the most directly comparable historical non-GAAP financial measures has been provided in Table E “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

Retrieved on: 
Thursday, May 2, 2024
Surgery, Science, Other Health, Veterinary, Nursing, Medical Supplies, Radiology, FDA, Other Science, Pharmaceutical, Diabetes, Research, Optical, Oncology, Mental Health, Medical Devices, Stem Cells, Infectious Diseases, Health Technology, Practice Management, Hospitals, Physical Therapy, Genetics, Managed Care, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, AIDS, Health, Immunoglobulin G, Automation, ADAS, Safety, Pharmacokinetics, Animal, Primate, Software, Therapy, Litre, Toxicokinetics, Drug development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

Key Points: 
  • Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.
  • The Gyrolab Generic Rodent ADA Kit fills an industry-wide need for a generic assay solution to expedite immunogenicity assessment.
  • Following the introduction of Gyrolab Generic Cyno ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents further expand the utility of the Gyrolab platform into earlier drug screening and preclinical phases of development.
  • Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

Hoag Receives $15 Million Gift from Philanthropists Julia and George Argyros at 2024 Nurse of the Year Celebration

Retrieved on: 
Friday, May 3, 2024
Magnet, Education, Cancer, Critical care, MSN, BSN, Hospital, Dream, Health, Heart, ANCC, Diabetes, Vanguard University, Culture, Certification, Patient, Argyros, RN, Sub, Evidence-based practice, Nursing

The generous gift brings the Argyros family's cumulative giving to Hoag to over $32 million, which has provided thousands of scholarships to Hoag nurses.

Key Points: 
  • The generous gift brings the Argyros family's cumulative giving to Hoag to over $32 million, which has provided thousands of scholarships to Hoag nurses.
  • This latest gift by the Argyros family builds upon their ongoing generous philanthropy directed to Hoag's nursing.
  • In 2016, Hoag established the Julia Argyros Center for Nursing Excellence in recognition of the family's dedication.
  • We want to thank Julia, George, Lisa and Stephanie Argyros for their overwhelming generosity, along with many other donors.

NOVEL OMEZA® OCM™ WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS

Retrieved on: 
Friday, May 3, 2024
Collagen, ProMedica, Mortality, University, Patient, Debridement, Diabetes, DFU, Conference, Foot, Diabetic foot ulcer, Peptide, PAR, European Wound Management Association, Wound healing, Clinical trial, EWMA, Plastic, Disease, Pharmaceutical industry

"We're extremely encouraged by the final results of our clinical trial evaluating Omeza®'s OCM™ platform, which showed significant healing—and in over half the cases, complete closure—of patients' diabetic wounds in twelve weeks or less.

Key Points: 
  • "We're extremely encouraged by the final results of our clinical trial evaluating Omeza®'s OCM™ platform, which showed significant healing—and in over half the cases, complete closure—of patients' diabetic wounds in twelve weeks or less.
  • Patients also reduced or eliminated weight bearing on the affected foot, known as offloading, to support healing.
  • A control group received current standards of wound care, including offloading, debridement, collagen, hypochlorite solution, and/or wound dressings containing silver alginate.
  • Five patients had DFUs that were greater than 12 months old, and 3 of those patients had 100% PAR.

Charting the Rise: MRI Technologies Soar with a 6.4% CAGR (2023-2028)

Retrieved on: 
Friday, May 3, 2024
Conditional sentence, Cancer, Health, Ohio State University, Diabetes, Patient, Helium, MRI, BCC, Intensive care medicine, Magnetic resonance imaging, Prevalence, Ageing, Medical imaging

BOSTON, May 3, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets expected to grow from $7.2 billion in 2023 and will reach $9.8 billion by the end of 2028 at a compound annual growth rate (CAGR) of 6.4% from 2023 through 2028"

Key Points: 
  • "Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets" is a study or report that looks at MRI technology used in healthcare and its worldwide market.
  • Siemens partnered with Ohio State University to develop a new MRI tech called High-V MRI (also known as .55T).
  • Low-field MRI is a new way of doing MRI scans with machines that have much lower power than usual.
  • Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets is driven by factors such as:
    Increasing demand for advanced imaging technologies: People want better imaging tools for their health.

Cheers to five years: IEHP's Victorville Community Wellness Center celebrates milestone

Retrieved on: 
Thursday, May 2, 2024
Tears, CWC, Health education, Housing, Health, Heart, Diabetes, Transport, Vaccine, High desert, Orosco, Food, Printable, Quality of life, Overalls, Warehouse

Inland Empire Health Plan's (IEHP) Community Wellness Center (CWC) in Victorville – formerly Community Resource Center – hosted an open house-style celebration on April 20, complete with tours of the space, class demonstrations and remarks from those who have been there from the beginning.

Key Points: 
  • Inland Empire Health Plan's (IEHP) Community Wellness Center (CWC) in Victorville – formerly Community Resource Center – hosted an open house-style celebration on April 20, complete with tours of the space, class demonstrations and remarks from those who have been there from the beginning.
  • "It's been really great to see the community embrace the center," said CWC Manager Delia Orosco.
  • The Victorville CWC opened in 2019 as a Community Resource Center with a mission to provide direct access to optimal health.
  • The Victorville Community Wellness Center is located at 12353 Mariposa Road, Suites C2 and C3, and is open from 9 a.m.-6 p.m., Monday through Friday, and 9 a.m.-1 p.m., Saturdays.

WELL Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI

Retrieved on: 
Thursday, May 2, 2024
Conditional sentence, Risk, AIDX, Chronic condition, Health, Diabetes, TSX, Chronic obstructive pulmonary disease, Data science, Patient, Statistic, Physician, Hypertension, WELL, Chronic kidney disease, Pharmaceutical industry

This enhanced version which features advanced chronic disease screening arrives just six months after the initial launch, which was primarily focused on rare disease detection.

Key Points: 
  • This enhanced version which features advanced chronic disease screening arrives just six months after the initial launch, which was primarily focused on rare disease detection.
  • Dr. Michael Frankel, Chief Medical Officer of WELL, commented on the new capabilities "Adding chronic disease detection is a game-changer for our AI powered physician co-pilot tools.
  • The technology behind WAIDS is powered by HEALWELL AI who has been helping physicians save lives for the past four years with its best-in-class rare disease detection capabilities.
  • Chronic diseases and the percentage of Canadians who have them include conditions like Diabetes 11%, Chronic Obstructive Pulmonary Disease 10%, Heart Disease 8%, and Chronic Kidney Disease 11-13%2 .